Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has received a non-prescription license for alli, a drug indicated for weight loss in adults, with a BMI 28kg/m2 or more, when used along with a reduced calorie, lower-fat diet.
Subscribe to our email newsletter
GlaxoSmithKline (GSK) said that it is the first time the European Commission has approved a non-prescription product for weight loss.
The centrally approved marketing authorization means GSK can now introduce alli for adults with a body mass index of 28kg/m2 or more, in all 27 EU member countries. Plans are underway to launch alli in the coming months.
Manfred Scheske, president of GSK Consumer Healthcare Europe, said: “alli, in the US, has successfully helped millions of users lose weight gradually and steadily, and adopt a healthy lifestyle. We are very excited about the opportunity to create similar success in Europe and we will be launching alli in pharmacies throughout Europe soon.”